Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
Phase 1
- Conditions
- Macular DegenerationChoroidal Neovascularization
- First Posted Date
- 2004-12-23
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Theragenics Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT00100087
- Locations
- 🇺🇸
Theragenics Clinical Site, Raleigh / Durham, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath